Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Vaccine. 2008 Dec 9;26(52):6883-93. doi: 10.1016/j.vaccine.2008.09.084. Epub 2008 Oct 20.

Safety and immunogenicity of recombinant poxvirus HIV-1 vaccines in young adults on highly active antiretroviral therapy.

Author information

  • 1Pediatrics and Molecular Medicine, University of Massachusetts Medical School, Worcester, MA, USA. thomas.greenough@umassmed.edu

Abstract

A trial to evaluate the safety and immunogenicity of recombinant modified vaccinia Ankara (MVA) and fowlpox (FP) vectors expressing multiple HIV-1 proteins was conducted in twenty HIV-1 infected youth with suppressed viral replication on HAART. The MVA and FP-based multigene HIV-1 vaccines were safe and well tolerated. Increased frequencies of HIV-1 specific CD4+ proliferative responses and cytokine secreting cells were detected following immunization. Increased frequencies and breadth of HIV-1 specific CD8 T-cell responses were also detected. Plasma HIV-1-specific antibody levels and neutralizing activity were unchanged following vaccination. Poxvirus-based vaccines may merit further study in therapeutic vaccine protocols.

PMID:
18940219
[PubMed - indexed for MEDLINE]
PMCID:
PMC2845914
Free PMC Article

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk